Since the introduction of implantable cardiac pacemakers in 1958 and implantable cardioverter-defibrillators in 1980, these devices have been proven to save and prolong lives. Pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy are deemed life-sustaining therapies. Despite these life-saving technologies, all patients ultimately will reach the end of their lives from either their heart disease or development of a terminal illness. Clinicians may be faced with patient and family requests to withdraw these life-sustaining therapies. The purpose of this article is to educate clinicians about the legal and ethical principles that underlie withdrawal of life-sustaining therapies such as device deactivation and to highlight the importance of proactive communication with patients and families in these situations.
Skip Nav Destination
Symposium Cardiac Implantable Electronic Devices| October 01 2015
Considerations in Patients With Cardiac Implantable Electronic Devices at End of Life
AACN Adv Crit Care (2015) 26 (4): 356–363.
- Views Icon Views
- Share Icon Share
Melanie T. Gura; Considerations in Patients With Cardiac Implantable Electronic Devices at End of Life. AACN Adv Crit Care 1 October 2015; 26 (4): 356–363. doi: https://doi.org/10.4037/NCI.0000000000000111
Download citation file: